Among SASP factors, VEGF levels are elevated in CF patients’ serum and BALF, potentially contributing to bronchiectasis-associated angiogenesis [114], negatively correlating with hypoxia, and being reduced by antibiotic therapy [115]. The gene discussed is VEGFA; the disease is cystic fibrosis.